- Home
- SGA vs VIGL Comparison
SGA vs VIGL Comparison
Compare SGA & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- VIGL
- Stock Information
- Founded
- SGA 1986
- VIGL 2020
- Country
- SGA United States
- VIGL United States
- Employees
- SGA N/A
- VIGL N/A
- Industry
- SGA Broadcasting
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- VIGL Health Care
- Exchange
- SGA Nasdaq
- VIGL Nasdaq
- Market Cap
- SGA 79.0M
- VIGL 89.3M
- IPO Year
- SGA 1992
- VIGL 2022
- Fundamental
- Price
- SGA $12.03
- VIGL $3.03
- Analyst Decision
- SGA
- VIGL Strong Buy
- Analyst Count
- SGA 0
- VIGL 5
- Target Price
- SGA N/A
- VIGL $21.00
- AVG Volume (30 Days)
- SGA 12.1K
- VIGL 642.5K
- Earning Date
- SGA 03-06-2025
- VIGL 03-25-2025
- Dividend Yield
- SGA 8.31%
- VIGL N/A
- EPS Growth
- SGA N/A
- VIGL N/A
- EPS
- SGA 0.75
- VIGL N/A
- Revenue
- SGA $110,669,000.00
- VIGL N/A
- Revenue This Year
- SGA N/A
- VIGL N/A
- Revenue Next Year
- SGA $2.64
- VIGL N/A
- P/E Ratio
- SGA $16.03
- VIGL N/A
- Revenue Growth
- SGA N/A
- VIGL N/A
- 52 Week Low
- SGA $10.75
- VIGL $1.49
- 52 Week High
- SGA $24.67
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- SGA 42.96
- VIGL 77.87
- Support Level
- SGA $12.23
- VIGL $2.71
- Resistance Level
- SGA $12.94
- VIGL $2.95
- Average True Range (ATR)
- SGA 0.31
- VIGL 0.21
- MACD
- SGA -0.08
- VIGL 0.03
- Stochastic Oscillator
- SGA 1.98
- VIGL 86.18
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets and It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.